Safety, Tolerability and Pharmacokinetics of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients

Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis

NCT02566044 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients

NCT02190604 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis

NCT03029455 ·Status: COMPLETED ·Phase: PHASE1

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients With Cystic Fibrosis

NCT06429176 ·Status: RECRUITING ·Phase: PHASE2

Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

NCT01710644 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)

NCT05111145 ·Status: COMPLETED ·Phase: PHASE3

BI 443651 Multiple Rising Dose in Healthy Volunteers Followed by a Cross-over in CF Subjects

NCT02976519 ·Status: COMPLETED ·Phase: PHASE1

MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9)

NCT02934139 ·Status: COMPLETED ·Phase: PHASE1

Safety and Tolerability Study of Liquid Alpha1 Proteinase Inhibitor (API) in Subjects With Cystic Fibrosis

NCT01347190 ·Status: COMPLETED ·Phase: PHASE1

Study Assessing PTI-428 Safety, Tolerability, Pharmacokinetics and Effect in Subjects With Cystic Fibrosis

NCT03591094 ·Status: COMPLETED ·Phase: PHASE2

Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis

NCT02718495 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Safety, Tolerability, and Pharmacokinetics of PTI-808, PTI-801, and PTI-428 Combination Therapy in Subjects With Cystic Fibrosis

NCT03500263 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation

NCT06861413 ·Status: COMPLETED ·Phase: PHASE1

PK Study of N91115 in Cystic Fibrosis Patients

NCT02227888 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis Subjects

NCT03093714 ·Status: COMPLETED ·Phase: PHASE1

A Safety and Tolerability Study OF PUR118 In Subjects With Cystic Fibrosis

NCT01543191 ·Status: COMPLETED ·Phase: PHASE1

An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing Mutations

NCT02934698 ·Status: COMPLETED ·Phase: PHASE3

A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis

NCT03911713 ·Status: COMPLETED ·Phase: PHASE2

Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose Tolerance

NCT02955888 ·Status: TERMINATED ·Phase: PHASE2

Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation

NCT02275936 ·Status: COMPLETED ·Phase: PHASE1

A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis

NCT02951182 ·Status: COMPLETED ·Phase: PHASE2

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QAU145 in Patients With Cystic Fibrosis

NCT00506792 ·Status: COMPLETED ·Phase: PHASE2

A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

NCT05033080 ·Status: COMPLETED ·Phase: PHASE3

28 Day Repeat Dose in Cystic Fibrosis Patients

NCT00903201 ·Status: COMPLETED ·Phase: PHASE2

Effect of Chronic Incretin-based Therapy in Cystic Fibrosis

NCT01879228 ·Status: COMPLETED ·Phase: NA